Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Vestal Point Capital LP

Vestal Point Capital LP lifted its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,180,000 shares of the biotechnology company's stock after acquiring an additional 180,000 shares during the period. Astria Therapeutics makes up 2.2% of Vestal Point Capital LP's portfolio, making the stock its 16th biggest position. Vestal Point Capital LP owned about 7.41% of Astria Therapeutics worth $37,369,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in Astria Therapeutics by 101.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company's stock worth $431,000 after purchasing an additional 19,735 shares during the period. SG Americas Securities LLC raised its position in Astria Therapeutics by 51.3% in the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company's stock valued at $190,000 after purchasing an additional 7,218 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Astria Therapeutics during the fourth quarter worth about $107,000. Rhumbline Advisers grew its stake in shares of Astria Therapeutics by 2.3% in the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock valued at $556,000 after buying an additional 1,381 shares in the last quarter. Finally, New York State Common Retirement Fund grew its stake in shares of Astria Therapeutics by 67.0% in the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company's stock valued at $96,000 after buying an additional 4,300 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ATXS. HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. JMP Securities assumed coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an "outperform" rating and a $26.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $47.00 target price on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Citizens Jmp upgraded shares of Astria Therapeutics to a "strong-buy" rating in a research note on Friday, January 31st. Finally, Wedbush reaffirmed an "outperform" rating and set a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $30.00.

Astria Therapeutics Trading Up 4.1%

NASDAQ ATXS traded up $0.16 during mid-day trading on Thursday, reaching $4.08. 943,267 shares of the company's stock traded hands, compared to its average volume of 372,382. Astria Therapeutics, Inc. has a 1-year low of $3.56 and a 1-year high of $12.92. The company has a fifty day simple moving average of $4.85 and a 200-day simple moving average of $7.24. The company has a market cap of $230.25 million, a price-to-earnings ratio of -1.95 and a beta of 0.45.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10). Equities research analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.